Brief: NRX Pharmaceuticals Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq On Oct 17
23/10/2023 21:38
Oct 23 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS INC - ON OCTOBER 17 RECEIVED NOTICE
OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Further company coverage: NRXP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview